Other FASN inhibitors can be explored for the CSN6-overexpressing cancer as well, including IPI-9119,55 C75, EGCG, flavonoid2 and several other inhibitors TVB-2640.56–58 It will be an exciting avenue for using these inhibitors in cancer prevention or therapy; for examples, in CRC patients when FASN expression was prognostically detrimental59 or in breast cancer patients with metastasis.60 This evidence concerns the gene FASN and breast carcinoma.